Pub Date : 1900-01-01DOI: 10.4103/2356-8062.159994
M. Halaw, M. A. Abu Shady, Y. Eid, A. EL Sherbeney, W. Mohamed
Objective The aim of this study was to evaluate vitamin D level in type 2 diabetic patients before and after treatment with pioglitazone and assess any possible relationship with type 2 diabetic patients who are pioglitazone naive. Participants and Methods The study included 50 female participants; of them, 20 were healthy female participants who served as controls and 30 were pioglitazone-naive diabetic patients. All individuals were subjected to history taking and clinical examination, including fasting blood sugar, 2 h postprandial, glycosylated hemoglobin (HbA1c), lipid profile test (total cholesterol, HDL, LDL, triglycerides), kidney function tests (serum creatinine and calculated glomerular filtration rate), and evaluation of serum calcium, phosphorus, and alkaline phosphatase and serum 25-hydroxy vitamin D (by enzyme linked immunosorbant assay) before (basal) and after 3 months of treatment with pioglitazone. Results There was an nonsignificant elevation of vitamin D in group 2b (diabetic patients after using pioglitazone for 3 months), in comparison with vitamin D level in group 2a (diabetic patients before using pioglitazone) (P = 0.117). Vitamin D levels were found to be inversely associated with HbA1c levels in type 2 diabetic patients (P = 0.000 linear regression analysis); it was also found to be inversely associated with fasting and 2 h postprandial blood sugar levels (P < 0.000). Conclusion Vitamin D could impact glycemic control in terms of the inverse relation of vitamin D with HbA1c%, and at the same time poor glycemic control could impact vitamin D status in uncontrolled diabetic patients. Thiazolidinediones do not have significant effect on vitamin D level in female diabetic patients.
{"title":"Study of vitamin D level in type 2 diabetic patients before and after treatment with pioglitazone","authors":"M. Halaw, M. A. Abu Shady, Y. Eid, A. EL Sherbeney, W. Mohamed","doi":"10.4103/2356-8062.159994","DOIUrl":"https://doi.org/10.4103/2356-8062.159994","url":null,"abstract":"Objective The aim of this study was to evaluate vitamin D level in type 2 diabetic patients before and after treatment with pioglitazone and assess any possible relationship with type 2 diabetic patients who are pioglitazone naive. Participants and Methods The study included 50 female participants; of them, 20 were healthy female participants who served as controls and 30 were pioglitazone-naive diabetic patients. All individuals were subjected to history taking and clinical examination, including fasting blood sugar, 2 h postprandial, glycosylated hemoglobin (HbA1c), lipid profile test (total cholesterol, HDL, LDL, triglycerides), kidney function tests (serum creatinine and calculated glomerular filtration rate), and evaluation of serum calcium, phosphorus, and alkaline phosphatase and serum 25-hydroxy vitamin D (by enzyme linked immunosorbant assay) before (basal) and after 3 months of treatment with pioglitazone. Results There was an nonsignificant elevation of vitamin D in group 2b (diabetic patients after using pioglitazone for 3 months), in comparison with vitamin D level in group 2a (diabetic patients before using pioglitazone) (P = 0.117). Vitamin D levels were found to be inversely associated with HbA1c levels in type 2 diabetic patients (P = 0.000 linear regression analysis); it was also found to be inversely associated with fasting and 2 h postprandial blood sugar levels (P < 0.000). Conclusion Vitamin D could impact glycemic control in terms of the inverse relation of vitamin D with HbA1c%, and at the same time poor glycemic control could impact vitamin D status in uncontrolled diabetic patients. Thiazolidinediones do not have significant effect on vitamin D level in female diabetic patients.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"81 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128626229","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.159986
A. Kaseb, Lianchun Xiao, R. Naguib, Wafaa El-Shikh, Manal M. Hassan, H. Hassabo, Jeong‐Hoon Lee, Jung‐Hwan Yoon, Hyo‐suk Lee, Y. Chae, J. Abbruzzese, Jeffrey S. Morris
Background The Child-Turcotte-Pugh (CTP) score inaccurately predicts survival in patients with chronic liver disease, including hepatocellular carcinoma (HCC), yet remains the standard tool for assessing hepatic reserve and guiding therapeutic decisions. CTP scoring relies on objective laboratory values for albumin, bilirubin, and prothrombin time and subjective clinical grading of hepatic encephalopathy and ascites. As liver production of insulin-like growth factor-1 (IGF-1) is significantly reduced in patients with cirrhosis, we hypothesized that IGF-1 could be a valid surrogate for hepatic reserve to replace the subjective parameters in CTP scores. Materials and methods We prospectively enrolled patients and collected data and retrospectively tested plasma IGF-1 levels in four independent cohorts: two HCC cohorts from the USA [n = 310 (training set) and n = 99 (validation set 1)]; one HCC cohort from Korea [n = 188 (validation set 2)]; and one cirrhosis cohort from Egypt [n = 71 (validation set 3)]. Recursive partitioning identified within the training set three optimal IGF-1 ranges that correlated with survival: >50 ng/ml = 1 point; 26-50 ng/ml = 2 points; and <26 ng/ml = 3 points. We modified the CTP score by replacing ascites and encephalopathy grading with IGF-1 values, subjected both the resulting IGF score and the CTP score to log-rank analysis, and quantified the prognostic values with C-statistics to compare the scores′ performance in all cohorts. Results The IGF score was significantly more accurate in predicting survival and improved the stratification of all CTP classes in the training and validation cohorts. Conclusion The new IGF score is simple and blood-based, and validated well on multiple independent HCC cohorts. It could identify a subpopulation of patients who may benefit from active therapy because of their preserved hepatic reserve, as distinct from patients for whom therapy can be deferred or avoided.
{"title":"Development and validation of an IGF-1-modified Child-Pugh score to risk-stratify hepatocellular carcinoma patients","authors":"A. Kaseb, Lianchun Xiao, R. Naguib, Wafaa El-Shikh, Manal M. Hassan, H. Hassabo, Jeong‐Hoon Lee, Jung‐Hwan Yoon, Hyo‐suk Lee, Y. Chae, J. Abbruzzese, Jeffrey S. Morris","doi":"10.4103/2356-8062.159986","DOIUrl":"https://doi.org/10.4103/2356-8062.159986","url":null,"abstract":"Background The Child-Turcotte-Pugh (CTP) score inaccurately predicts survival in patients with chronic liver disease, including hepatocellular carcinoma (HCC), yet remains the standard tool for assessing hepatic reserve and guiding therapeutic decisions. CTP scoring relies on objective laboratory values for albumin, bilirubin, and prothrombin time and subjective clinical grading of hepatic encephalopathy and ascites. As liver production of insulin-like growth factor-1 (IGF-1) is significantly reduced in patients with cirrhosis, we hypothesized that IGF-1 could be a valid surrogate for hepatic reserve to replace the subjective parameters in CTP scores. Materials and methods We prospectively enrolled patients and collected data and retrospectively tested plasma IGF-1 levels in four independent cohorts: two HCC cohorts from the USA [n = 310 (training set) and n = 99 (validation set 1)]; one HCC cohort from Korea [n = 188 (validation set 2)]; and one cirrhosis cohort from Egypt [n = 71 (validation set 3)]. Recursive partitioning identified within the training set three optimal IGF-1 ranges that correlated with survival: >50 ng/ml = 1 point; 26-50 ng/ml = 2 points; and <26 ng/ml = 3 points. We modified the CTP score by replacing ascites and encephalopathy grading with IGF-1 values, subjected both the resulting IGF score and the CTP score to log-rank analysis, and quantified the prognostic values with C-statistics to compare the scores′ performance in all cohorts. Results The IGF score was significantly more accurate in predicting survival and improved the stratification of all CTP classes in the training and validation cohorts. Conclusion The new IGF score is simple and blood-based, and validated well on multiple independent HCC cohorts. It could identify a subpopulation of patients who may benefit from active therapy because of their preserved hepatic reserve, as distinct from patients for whom therapy can be deferred or avoided.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"15 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131701511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.184398
S. Zaki, Osama Hassan Shehata, Akram A Deghedi, Shehab Mohamed Sami, Rehab Hussien Mohamed Mersal
Introduction Cardiovascular disease is the leading cause of mortality in patients with end-stage renal disease (ESRD) and is attributed to a combination of traditional and nontraditional risk factors. In recent years, there has been an increasing recognition of a very high prevalence of cardiovascular calcification in the ESRD population, including patients receiving hemodialysis (HD) and peritoneal dialysis. The mechanism is multifactorial, including structural and functional abnormalities in the large vessels, disorders in calcium (Ca2+) and phosphate (P) metabolism, vascular smooth muscle cells changes, and regulatory markers such as fetuin-A and osteoprotegerin (OPG). Aim of the work The aim of the present study was to determine the utility of multislice computed tomography (MSCT) for the assessment of coronary artery calcifications (CACs) and to identify the potential risks for CAC, including calcification regulating proteins such as fetuin-A and OPG, among patients with ESRD on maintenance dialysis (HD and peritoneal dialysis). Patients and methods This study included 70 patients who were divided into four groups: 20 patients on continuous ambulatory peritoneal dialysis (CAPD), 10 patients with ESRD stage 4 and 5, 30 patients on HD (subdivided into three subgroups according to the duration of HD: for 1–5 years, for 5–10 years, and for more than 10 years), and 10 healthy controls. They were subjected to complete history-taking, thorough clinical examination, investigations including serum level of fetuin-A, serum level of OPG by using the enzyme-linked immunosorbent assay technique, as well as MSCT imaging using 128-detector scanners for the quantification of CAC (calcium scoring) by using the Agatston method. Results There was a significant decrease in the serum level of fetuin-A in patients on HD compared with patients on CAPD, as well as in healthy controls. Moreover, there was a significant increase in the serum level of OPG in patients on HD compared with its level in CAPD patients as well as in healthy controls. The calcium scoring was significantly high in the HD group of patients (group IIa) (P = 0.032), with a low calcium score in CAPD patients group (group I) (P = 0.036) compared with healthy controls in group IV. CAC scoring was correlated positively and significantly with serum level of OPG in the total samples (r = 0.345* and P = 0.0270). On the other hand, it was negatively and significantly correlated with the serum level of fetuin-A in the total samples (r = −0.411FNx01 and P = 0.002). Conclusion Fetuin-A and OPG can be early and important markers of vascular calcifications in patients on dialysis; in addition, calcium scoring using MSCT provides a noninvasive method of assessment of the vascular calcification in these patients. Vascular calcification is more evident in patients on HD than in patients treated using CAPD; this can help in the selection of the modality of treatment of patients with ESRD, as well as early detect
心血管疾病是终末期肾病(ESRD)患者死亡的主要原因，并归因于传统和非传统危险因素的结合。近年来，越来越多的人认识到ESRD人群中心血管钙化的患病率非常高，包括接受血液透析(HD)和腹膜透析的患者。其机制是多因素的，包括大血管的结构和功能异常，钙(Ca2+)和磷酸盐(P)代谢紊乱，血管平滑肌细胞的变化以及调节标志物，如胎蛋白a和骨保护素(OPG)。本研究的目的是确定多层计算机断层扫描(MSCT)用于评估冠状动脉钙化(CACs)的效用，并确定CAC的潜在风险，包括钙化调节蛋白，如胎蛋白a和OPG，在维持透析(HD和腹膜透析)的ESRD患者中。患者和方法本研究纳入70例患者，分为4组:20例持续动态腹膜透析(CAPD)患者，10例ESRD 4期和5期患者，30例HD患者(根据HD持续时间分为3个亚组:1-5年，5 - 10年和10年以上)，10例健康对照。他们接受了完整的病史记录，彻底的临床检查，包括使用酶联免疫吸附测定技术进行血清胎儿素a水平、血清OPG水平的调查，以及使用Agatston法使用128检测器扫描仪进行MSCT成像以定量CAC(钙评分)。结果与CAPD患者及健康对照组相比，HD患者血清中胎儿素a水平明显降低。此外，与CAPD患者和健康对照组相比，HD患者的血清OPG水平显著升高。HD组(IIa组)患者钙评分显著高于健康对照组(P = 0.032)， CAPD组(I组)患者钙评分显著低于健康对照组(P = 0.036)。CAC评分与总样本血清OPG水平呈显著正相关(r = 0.345*， P = 0.0270)。另一方面，与总样本血清中胎儿素a水平呈显著负相关(r = - 0.411FNx01, P = 0.002)。结论胎儿素a和OPG是透析患者血管钙化的早期重要指标;此外，使用MSCT进行钙评分提供了一种评估这些患者血管钙化的无创方法。血管钙化在HD患者中比使用CAPD治疗的患者更明显;这有助于选择ESRD患者的治疗方式，以及早期发现和预防接受透析(HD或CAPD)治疗的ESRD患者的心血管(CVS)疾病。
{"title":"Evaluation of coronary artery calcification using multislice computed tomography in patients on dialysis: association with fetuin-A and osteoprotegerin","authors":"S. Zaki, Osama Hassan Shehata, Akram A Deghedi, Shehab Mohamed Sami, Rehab Hussien Mohamed Mersal","doi":"10.4103/2356-8062.184398","DOIUrl":"https://doi.org/10.4103/2356-8062.184398","url":null,"abstract":"Introduction Cardiovascular disease is the leading cause of mortality in patients with end-stage renal disease (ESRD) and is attributed to a combination of traditional and nontraditional risk factors. In recent years, there has been an increasing recognition of a very high prevalence of cardiovascular calcification in the ESRD population, including patients receiving hemodialysis (HD) and peritoneal dialysis. The mechanism is multifactorial, including structural and functional abnormalities in the large vessels, disorders in calcium (Ca2+) and phosphate (P) metabolism, vascular smooth muscle cells changes, and regulatory markers such as fetuin-A and osteoprotegerin (OPG). Aim of the work The aim of the present study was to determine the utility of multislice computed tomography (MSCT) for the assessment of coronary artery calcifications (CACs) and to identify the potential risks for CAC, including calcification regulating proteins such as fetuin-A and OPG, among patients with ESRD on maintenance dialysis (HD and peritoneal dialysis). Patients and methods This study included 70 patients who were divided into four groups: 20 patients on continuous ambulatory peritoneal dialysis (CAPD), 10 patients with ESRD stage 4 and 5, 30 patients on HD (subdivided into three subgroups according to the duration of HD: for 1–5 years, for 5–10 years, and for more than 10 years), and 10 healthy controls. They were subjected to complete history-taking, thorough clinical examination, investigations including serum level of fetuin-A, serum level of OPG by using the enzyme-linked immunosorbent assay technique, as well as MSCT imaging using 128-detector scanners for the quantification of CAC (calcium scoring) by using the Agatston method. Results There was a significant decrease in the serum level of fetuin-A in patients on HD compared with patients on CAPD, as well as in healthy controls. Moreover, there was a significant increase in the serum level of OPG in patients on HD compared with its level in CAPD patients as well as in healthy controls. The calcium scoring was significantly high in the HD group of patients (group IIa) (P = 0.032), with a low calcium score in CAPD patients group (group I) (P = 0.036) compared with healthy controls in group IV. CAC scoring was correlated positively and significantly with serum level of OPG in the total samples (r = 0.345* and P = 0.0270). On the other hand, it was negatively and significantly correlated with the serum level of fetuin-A in the total samples (r = −0.411FNx01 and P = 0.002). Conclusion Fetuin-A and OPG can be early and important markers of vascular calcifications in patients on dialysis; in addition, calcium scoring using MSCT provides a noninvasive method of assessment of the vascular calcification in these patients. Vascular calcification is more evident in patients on HD than in patients treated using CAPD; this can help in the selection of the modality of treatment of patients with ESRD, as well as early detect","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"48 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133881369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/ejode.ejode_26_17
M. Halawa, Abeer Abdullah, N. Ibrahim, Ahmed El-Sabawy
Background Chemerin is a novel adipokine, which is suggested to play a role in the development of type 2 diabetes mellitus (T2DM) and its chronic complications. Diabetic retinopathy (DR) is a common complication of diabetes, caused by diabetic microvascular lesions. Objective To investigate the relationship between serum chemerin level and DR in T2DM. Study design Eighty participants were enrolled in the study and were divided into three groups: group I included 40 patients with T2DM complicated with DR, and this group was further subdivided to proliferative diabetic retinopathy (PDR) and nonproliferative diabetic retinopathy (NPDR); group II included 20 patients with T2DM not complicated with DR; and group III included 20 apparently healthy patients representing control group. Anthropometric and laboratory measurements including serum chemerin levels were assessed, and values were analyzed to compare the differences among the groups. Results Chemerin level was significantly higher in group I than that in both group II and group III (158.4±25.7 vs. 127.4±20.1 and 116.6±20.3 ng/dl, respectively; P<0.01). Moreover, chemerin level was significantly higher in the PDR group than that in NPDR group (167.7±28.4 vs. 152.2±22.2 ng/dl; P<0.05). Otherwise, no significant difference of chemerin level between group II and group III was found (P=0.135). Conclusion Serum chemerin levels were elevated in patients with T2DM with DR than those without DR and were elevated in patients with PDR than NPDR, suggesting that chemerin may be involved in the development of PDR.
Chemerin是一种新型的脂肪因子，被认为在2型糖尿病(T2DM)及其慢性并发症的发展中发挥作用。糖尿病视网膜病变(DR)是糖尿病的常见并发症，由糖尿病微血管病变引起。目的探讨T2DM患者血清趋化素水平与DR的关系。80名受试者入组，分为3组:1组包括40例T2DM合并DR患者，该组进一步细分为增殖性糖尿病视网膜病变(PDR)和非增殖性糖尿病视网膜病变(NPDR);II组包括20例未合并DR的T2DM患者;第三组为20例明显健康的患者，作为对照组。评估人体测量和实验室测量，包括血清趋化素水平，并分析其值以比较各组之间的差异。结果I组Chemerin水平显著高于II组和III组(158.4±25.7 vs 127.4±20.1和116.6±20.3 ng/dl);P < 0.01)。PDR组趋化素水平显著高于NPDR组(167.7±28.4∶152.2±22.2 ng/dl;P < 0.05)。此外，II组与III组chemerin水平差异无统计学意义(P=0.135)。结论T2DM合并DR患者血清趋化素水平高于无DR患者，PDR患者血清趋化素水平高于NPDR患者，提示趋化素可能参与了PDR的发生。
{"title":"Chemerin is associated with diabetic retinopathy in type 2 diabetes","authors":"M. Halawa, Abeer Abdullah, N. Ibrahim, Ahmed El-Sabawy","doi":"10.4103/ejode.ejode_26_17","DOIUrl":"https://doi.org/10.4103/ejode.ejode_26_17","url":null,"abstract":"Background Chemerin is a novel adipokine, which is suggested to play a role in the development of type 2 diabetes mellitus (T2DM) and its chronic complications. Diabetic retinopathy (DR) is a common complication of diabetes, caused by diabetic microvascular lesions. Objective To investigate the relationship between serum chemerin level and DR in T2DM. Study design Eighty participants were enrolled in the study and were divided into three groups: group I included 40 patients with T2DM complicated with DR, and this group was further subdivided to proliferative diabetic retinopathy (PDR) and nonproliferative diabetic retinopathy (NPDR); group II included 20 patients with T2DM not complicated with DR; and group III included 20 apparently healthy patients representing control group. Anthropometric and laboratory measurements including serum chemerin levels were assessed, and values were analyzed to compare the differences among the groups. Results Chemerin level was significantly higher in group I than that in both group II and group III (158.4±25.7 vs. 127.4±20.1 and 116.6±20.3 ng/dl, respectively; P<0.01). Moreover, chemerin level was significantly higher in the PDR group than that in NPDR group (167.7±28.4 vs. 152.2±22.2 ng/dl; P<0.05). Otherwise, no significant difference of chemerin level between group II and group III was found (P=0.135). Conclusion Serum chemerin levels were elevated in patients with T2DM with DR than those without DR and were elevated in patients with PDR than NPDR, suggesting that chemerin may be involved in the development of PDR.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"90 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114878924","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.197578
Magdy Zohairy, A. Raya, A. Deghady, Riham Soliman
Background Systemic sclerosis (SSc) is a generalized connective tissue disorder characterized by sclerotic changes in the skin and internal organs. Interleukin-33 (IL-33) is a newly reported cytokine of the IL-1 family. Aim of the work The aim of this study was to determine serum levels of IL-33 in SSc patients and evaluate its association with clinical manifestations and disease subset. Patients and methods The patients in this study were divided into group A and group B. Group A included 30 adult patients with SSc, which was subdivided into diffuse systemic sclerosis (dSSc) and limited systemic sclerosis (lSSc). All cases were diagnosed according to the American College of Rheumatology criteria for SSc. Group B included 15 healthy adults (age and sex matched) who served as controls. Serum IL-33 levels were examined by means of enzyme-linked immunosorbent assay in 30 patients with SSc and in 15 healthy individuals. Skin assessment was done using the modified Rodnan skin score. Results IL-33 was increased in all SSc patients compared with controls. The levels of IL-33 were significantly higher in the dSSc subset compared with the lSSc subset. IL-33 is highly correlated to the presence of pulmonary fibrosis, Raynaud’s phenomenon, pitting scars and ulcers, pulmonary hypertension, joint contracture, and modified Rodnan skin score. Thus, IL-33 levels were increased in SSc patients and correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis. Therefore, IL-33 possibly plays a role in cutaneous and pulmonary fibrosis in SSc patients. Conclusion IL-33 may have a significant role in the pathogenesis of SSc. IL-33 serum levels paralleled the severity of the disease subset. Understanding of IL-33 functions is important for the development of new therapeutic approaches including IL-33 inhibitors and IL-33 receptor blockers as a therapeutic target.
{"title":"Interleukin-33 in systemic sclerosis: correlation with clinical manifestations and disease subset","authors":"Magdy Zohairy, A. Raya, A. Deghady, Riham Soliman","doi":"10.4103/2356-8062.197578","DOIUrl":"https://doi.org/10.4103/2356-8062.197578","url":null,"abstract":"Background Systemic sclerosis (SSc) is a generalized connective tissue disorder characterized by sclerotic changes in the skin and internal organs. Interleukin-33 (IL-33) is a newly reported cytokine of the IL-1 family. Aim of the work The aim of this study was to determine serum levels of IL-33 in SSc patients and evaluate its association with clinical manifestations and disease subset. Patients and methods The patients in this study were divided into group A and group B. Group A included 30 adult patients with SSc, which was subdivided into diffuse systemic sclerosis (dSSc) and limited systemic sclerosis (lSSc). All cases were diagnosed according to the American College of Rheumatology criteria for SSc. Group B included 15 healthy adults (age and sex matched) who served as controls. Serum IL-33 levels were examined by means of enzyme-linked immunosorbent assay in 30 patients with SSc and in 15 healthy individuals. Skin assessment was done using the modified Rodnan skin score. Results IL-33 was increased in all SSc patients compared with controls. The levels of IL-33 were significantly higher in the dSSc subset compared with the lSSc subset. IL-33 is highly correlated to the presence of pulmonary fibrosis, Raynaud’s phenomenon, pitting scars and ulcers, pulmonary hypertension, joint contracture, and modified Rodnan skin score. Thus, IL-33 levels were increased in SSc patients and correlated with the extent of skin sclerosis and the severity of pulmonary fibrosis. Therefore, IL-33 possibly plays a role in cutaneous and pulmonary fibrosis in SSc patients. Conclusion IL-33 may have a significant role in the pathogenesis of SSc. IL-33 serum levels paralleled the severity of the disease subset. Understanding of IL-33 functions is important for the development of new therapeutic approaches including IL-33 inhibitors and IL-33 receptor blockers as a therapeutic target.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"62 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126611316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.178338
Magdy El-Zohairy, A. Abou-Raya, A. Degady, E. El-Said, M. Adel
Introduction Rheumatoid arthritis (RA) is a chronic systemic disease that primarily targets the synovium, leading to synovial inflammation and proliferation, loss of articular cartilage, and erosion of juxta-articular bone. Objective The aim of the work was to assess the role of serum monocyte chemoattractant protein-1 (MCP-1) as a marker of disease activity in RA and its correlation with different disease parameters. Patients and methods We assessed serum MCP-1 level in 40 RA patients and 20 age-matched and sex-matched healthy controls. We also assessed different clinical and laboratory disease parameters in RA patients - namely, swollen joint count, tender joint count, erythrocyte sedimentation rate, C-reactive protein (CRP), rheumatoid factor, anti-cyclic citrullinated peptide (ACCP), and 28-joint Disease Activity Score (DAS-28) (CRP). We correlated serum MCP-1 with disease activity and different disease parameters. Results Serum MCP-1 was significantly higher (P = 0.001) in the patient group (mean = 414, SD = 508.97) than in the control group (mean = 77.25, SD = 16.58). Serum level also correlated significantly with rheumatoid factor (P = 0.004), swollen joint count (P = 0.004), and with DAS-28 CRP score (0.034). There was no significant correlation between MCP-1 and tender joint count, erythrocyte sedimentation rate, CRP, or radiographic changes. Conclusion Serum MCP-1 is a useful biomarker in monitoring RA activity.
{"title":"Study of serum monocyte chemoattractant protein-1 as a marker of disease activity in rheumatoid arthritis patients","authors":"Magdy El-Zohairy, A. Abou-Raya, A. Degady, E. El-Said, M. Adel","doi":"10.4103/2356-8062.178338","DOIUrl":"https://doi.org/10.4103/2356-8062.178338","url":null,"abstract":"Introduction Rheumatoid arthritis (RA) is a chronic systemic disease that primarily targets the synovium, leading to synovial inflammation and proliferation, loss of articular cartilage, and erosion of juxta-articular bone. Objective The aim of the work was to assess the role of serum monocyte chemoattractant protein-1 (MCP-1) as a marker of disease activity in RA and its correlation with different disease parameters. Patients and methods We assessed serum MCP-1 level in 40 RA patients and 20 age-matched and sex-matched healthy controls. We also assessed different clinical and laboratory disease parameters in RA patients - namely, swollen joint count, tender joint count, erythrocyte sedimentation rate, C-reactive protein (CRP), rheumatoid factor, anti-cyclic citrullinated peptide (ACCP), and 28-joint Disease Activity Score (DAS-28) (CRP). We correlated serum MCP-1 with disease activity and different disease parameters. Results Serum MCP-1 was significantly higher (P = 0.001) in the patient group (mean = 414, SD = 508.97) than in the control group (mean = 77.25, SD = 16.58). Serum level also correlated significantly with rheumatoid factor (P = 0.004), swollen joint count (P = 0.004), and with DAS-28 CRP score (0.034). There was no significant correlation between MCP-1 and tender joint count, erythrocyte sedimentation rate, CRP, or radiographic changes. Conclusion Serum MCP-1 is a useful biomarker in monitoring RA activity.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"30 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126706681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/ejode.ejode_9_21
Rania Bahriz, Amr Elprawy, MohamadS Abd Alhamid Aladlany, Mohamed Atwa
{"title":"Evaluation of serum endocan as a marker of diabetic nephropathy","authors":"Rania Bahriz, Amr Elprawy, MohamadS Abd Alhamid Aladlany, Mohamed Atwa","doi":"10.4103/ejode.ejode_9_21","DOIUrl":"https://doi.org/10.4103/ejode.ejode_9_21","url":null,"abstract":"","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126118645","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.159990
S. Assaad, A. El-Aghoury, E. El-sharkawy, E. Azzam, M. Salah
Introduction Over the past few decades obesity has become a major burden on health worldwide. The prevalence of hypertension has increased with a significant increase in the prevalence of overweight and obesity. Recent studies indicate an important role of adipose tissue hormones called adipokines in obesity-associated complications. Apelin has recently been added to the family of adipokines. One of the physiologic functions of the apelin/APJ system is regulation of the cardiovascular function. The aim of this study was to determine the relation of serum apelin to obesity-associated hypertension as well as to myocardial performance. Patients and methods The study included 30 obese hypertensive patients, 30 obese nonhypertensive patients, and 25 age-matched and sex-matched controls. In all studied participants we determined the lipid profile, serum insulin, fasting blood glucose level, HOMA-IR, serum apelin, and echocardiographic results of left ventricular systolic and diastolic function. Results Higher levels of fasting blood glucose, fasting serum insulin, HOMA-IR, triglycerides, total cholesterol, and low-density lipoprotein were detected in obese hypertensive and nonhypertensive patients. Left ventricular mass index (LVMI) was increased in both obese hypertensive and nonhypertensive patients in comparison with healthy individuals. Left ventricular ejection fraction and E/A ratio were significantly lower in hypertensive obese versus nonhypertensive obese individuals (P = 0.004 and <0.001, respectively), whereas LVMI was higher in hypertensive versus nonhypertensive patients (P < 0.001). Apelin levels were significantly equally higher in obese hypertensive and nonhypertensive patients (6.10 ± 1.88 and 6.40 ± 1.60 ng/ml) compared with controls (4.22 ± 0.86 ng/ml, P < 0.001). In hypertensive obese individuals, serum apelin correlated negatively with left ventricular ejection fraction (P = 0.02) and directly with E/A ratio (P = 0.03). Conclusion Apelin levels are significantly higher in obese hypertensive and nonhypertensive patients. This increase might be a compensatory mechanism against myocardial dysfunction with obesity.
{"title":"Study of serum apelin and its relation to obesity-associated hypertension","authors":"S. Assaad, A. El-Aghoury, E. El-sharkawy, E. Azzam, M. Salah","doi":"10.4103/2356-8062.159990","DOIUrl":"https://doi.org/10.4103/2356-8062.159990","url":null,"abstract":"Introduction Over the past few decades obesity has become a major burden on health worldwide. The prevalence of hypertension has increased with a significant increase in the prevalence of overweight and obesity. Recent studies indicate an important role of adipose tissue hormones called adipokines in obesity-associated complications. Apelin has recently been added to the family of adipokines. One of the physiologic functions of the apelin/APJ system is regulation of the cardiovascular function. The aim of this study was to determine the relation of serum apelin to obesity-associated hypertension as well as to myocardial performance. Patients and methods The study included 30 obese hypertensive patients, 30 obese nonhypertensive patients, and 25 age-matched and sex-matched controls. In all studied participants we determined the lipid profile, serum insulin, fasting blood glucose level, HOMA-IR, serum apelin, and echocardiographic results of left ventricular systolic and diastolic function. Results Higher levels of fasting blood glucose, fasting serum insulin, HOMA-IR, triglycerides, total cholesterol, and low-density lipoprotein were detected in obese hypertensive and nonhypertensive patients. Left ventricular mass index (LVMI) was increased in both obese hypertensive and nonhypertensive patients in comparison with healthy individuals. Left ventricular ejection fraction and E/A ratio were significantly lower in hypertensive obese versus nonhypertensive obese individuals (P = 0.004 and <0.001, respectively), whereas LVMI was higher in hypertensive versus nonhypertensive patients (P < 0.001). Apelin levels were significantly equally higher in obese hypertensive and nonhypertensive patients (6.10 ± 1.88 and 6.40 ± 1.60 ng/ml) compared with controls (4.22 ± 0.86 ng/ml, P < 0.001). In hypertensive obese individuals, serum apelin correlated negatively with left ventricular ejection fraction (P = 0.02) and directly with E/A ratio (P = 0.03). Conclusion Apelin levels are significantly higher in obese hypertensive and nonhypertensive patients. This increase might be a compensatory mechanism against myocardial dysfunction with obesity.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"39 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123563002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.184402
S. Ooda, M. Elbelbesy, Nargues M. Hassanein, Ola Elgaddar, Hassan M Bachlah
Background Type 2 diabetes mellitus (T2DM) is a common multifactorial genetic disease. Adiponectin is a hormone produced solely by adipocytes and is a regulator of glucose and energy homeostasis. A number of genes and polymorphisms have been reproducibly associated with T2DM in a variety of studies. The gene ADIPOQ, encoding adiponectin, was found to be the main locus contributing to variations in adiponectin serum levels. Objective The aim of the work was to investigate the association between single-nucleotide polymorphism in exon 2 (45T/G) of the adiponectin gene with serum adiponectin level, and the occurrence of T2DM, which could allow proper management and genetic counseling for the high-risk carrier. Patients and methods The study included 40 patients with T2DM and 40 normal individuals with no family history of diabetes mellitus. BMI, serum fasting and postprandial glucose, lipid profile, fasting insulin, and adiponectin were measured. Molecular study for adiponectin 45T/G gene polymorphism was carried out. Results There was no statistically significant difference found when either genotype or allele frequencies were compared between the two groups. Conclusion Single-nucleotide polymorphism 45T/G of adiponectin gene was not associated with T2DM.
{"title":"Assessment of the association of the adiponectin gene single-nucleotide polymorphism 45T/G with type 2 diabetes mellitus in Egyptian diabetic patients","authors":"S. Ooda, M. Elbelbesy, Nargues M. Hassanein, Ola Elgaddar, Hassan M Bachlah","doi":"10.4103/2356-8062.184402","DOIUrl":"https://doi.org/10.4103/2356-8062.184402","url":null,"abstract":"Background Type 2 diabetes mellitus (T2DM) is a common multifactorial genetic disease. Adiponectin is a hormone produced solely by adipocytes and is a regulator of glucose and energy homeostasis. A number of genes and polymorphisms have been reproducibly associated with T2DM in a variety of studies. The gene ADIPOQ, encoding adiponectin, was found to be the main locus contributing to variations in adiponectin serum levels. Objective The aim of the work was to investigate the association between single-nucleotide polymorphism in exon 2 (45T/G) of the adiponectin gene with serum adiponectin level, and the occurrence of T2DM, which could allow proper management and genetic counseling for the high-risk carrier. Patients and methods The study included 40 patients with T2DM and 40 normal individuals with no family history of diabetes mellitus. BMI, serum fasting and postprandial glucose, lipid profile, fasting insulin, and adiponectin were measured. Molecular study for adiponectin 45T/G gene polymorphism was carried out. Results There was no statistically significant difference found when either genotype or allele frequencies were compared between the two groups. Conclusion Single-nucleotide polymorphism 45T/G of adiponectin gene was not associated with T2DM.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"26 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"124727469","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 1900-01-01DOI: 10.4103/2356-8062.197572
A. Ebeid, D. Hashad, M. Sadaka, Mohamed A. Elshafie, M. Sakr, Samah Idris
Objective The aim of this study was to evaluate the effects of albuminuria on different biochemical markers, different target organs, and subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Patients and methods Sixty T2DM patients were divided into three equal groups according to their levels of albuminuria − namely, normoalbuminuria, microalbuminuria, and macroalbuminuria. Renal function tests, glycemic status markers, serum electrolytes, high-sensitivity C-reactive protein, fibroblast growth factor 23, vitamin D, intact parathyroid hormone, and fractional excretion of phosphate (FePO4) were measured. Patients also underwent renal arterial duplex, Doppler echocardiography, and estimation of the carotid intima–media thickness. Results Blood urea nitrogen and creatinine clearance were significantly higher in patients with albuminuria. Fasting blood glucose, postprandial blood glucose, and glycosylated hemoglobin levels were significantly higher in patients with albuminuria. There were no statistically significant differences among the studied groups as regards serum electrolytes. Fibroblast growth factor 23 levels were significantly higher in patients with albuminuria. In patients with macroalbuminuria, vitamin D levels were significantly lower, whereas intact parathyroid hormone and high-sensitivity C-reactive protein levels were significantly higher. There were no statistically significant differences among the studied groups as regards FePO4. There were no statistically significant differences between the studied groups as regards renal resistive indices, presence or absence of left ventricular hypertrophy, or carotid intima–media thickness. Left ventricular ejection fraction was significantly lower in patients with albuminuria. Conclusion In T2DM patients with albuminuria (especially macroalbuminuria), several markers of renal complications are elevated, denoting a high-risk population for the development of end-stage renal disease. Moreover, markers of asymptomatic left ventricular systolic dysfunction were observed, denoting a higher risk for cardiovascular morbidity and mortality.
{"title":"Evaluation of different biochemical markers and imaging modalities in type 2 diabetes mellitus patients with and without albuminuria","authors":"A. Ebeid, D. Hashad, M. Sadaka, Mohamed A. Elshafie, M. Sakr, Samah Idris","doi":"10.4103/2356-8062.197572","DOIUrl":"https://doi.org/10.4103/2356-8062.197572","url":null,"abstract":"Objective The aim of this study was to evaluate the effects of albuminuria on different biochemical markers, different target organs, and subclinical atherosclerosis in patients with type 2 diabetes mellitus (T2DM). Patients and methods Sixty T2DM patients were divided into three equal groups according to their levels of albuminuria − namely, normoalbuminuria, microalbuminuria, and macroalbuminuria. Renal function tests, glycemic status markers, serum electrolytes, high-sensitivity C-reactive protein, fibroblast growth factor 23, vitamin D, intact parathyroid hormone, and fractional excretion of phosphate (FePO4) were measured. Patients also underwent renal arterial duplex, Doppler echocardiography, and estimation of the carotid intima–media thickness. Results Blood urea nitrogen and creatinine clearance were significantly higher in patients with albuminuria. Fasting blood glucose, postprandial blood glucose, and glycosylated hemoglobin levels were significantly higher in patients with albuminuria. There were no statistically significant differences among the studied groups as regards serum electrolytes. Fibroblast growth factor 23 levels were significantly higher in patients with albuminuria. In patients with macroalbuminuria, vitamin D levels were significantly lower, whereas intact parathyroid hormone and high-sensitivity C-reactive protein levels were significantly higher. There were no statistically significant differences among the studied groups as regards FePO4. There were no statistically significant differences between the studied groups as regards renal resistive indices, presence or absence of left ventricular hypertrophy, or carotid intima–media thickness. Left ventricular ejection fraction was significantly lower in patients with albuminuria. Conclusion In T2DM patients with albuminuria (especially macroalbuminuria), several markers of renal complications are elevated, denoting a high-risk population for the development of end-stage renal disease. Moreover, markers of asymptomatic left ventricular systolic dysfunction were observed, denoting a higher risk for cardiovascular morbidity and mortality.","PeriodicalId":260758,"journal":{"name":"Egyptian Journal of Obesity, Diabetes and Endocrinology","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"1900-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126377224","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：